Baseline characteristics differed between M/F pts w/ AS & nr-axSpA. Women were older at dz onset w/longer symptom duration & more joint dz and were less likely to be + HLA-B27 than men. Do you see this in your practice? #ABS0876 #ACR20 @RheumNow https://t.co/2goek1NiUW https://t.co/Uk8pmNP4Hr

• Gender Differences in Baseline Clinical Characteristics Among Patients with Ank…

Pooled analysis from MEASURE 1-5 showed SEC was effective for AS regardless of HLA-B27 status. HLA-B27+ pts had more therapeutic benefit vs. HLA-B27- pts. @RheumNow #ACR20 abs#0885 #ACRbest https://t.co/eD3ZGWxDkX

New treatments in Axial Spa at #ACR20. A significantly higher proportion of pts receiving Upadactinib vs placebo achieved reductions in all PGA of pain assessments and sustained to week 64 @RheumNow Abstr#369

Secukinumab has been used to treat spinal involvement in axial SpA. Secukinumab led to significant improvements in symptoms of peripheral arthritis in pts with AS. Significant improvements were seen in both tender and swollen joints @RheumNow #ACR20 Abstr#366

Check out my video on @rheumnow! #ACR20 Non-radiographic axSpa ACR Abstracts: Dr. Rachel Tate https://t.co/TVDdyZvOEA via @YouTube

• Non-radiographic axSpa ACR Abstracts: Dr. Rachel Tate - YouTube

RheumNow’s expanded coverage of the #ACR20 Annual meeting is sponsored in part by @Novartis. All content chosen by RheumNow & its Faculty.

Better outcomes (ASAS20 and ASAS40 @wk 52) seen in younger pts (possibly lower disease duration) when Secukinumab was given to ankylosing spondylitis pts. Early Dx in #AS! #ACR20 Abstr#0350 https://t.co/EKks0b1upc https://t.co/bxIH9lloI1

• https://meet.acrconvergence.org/meetings/virtual/hqhCmkpwMY8bzrG2j

Emerging trend #MachineLearning - SpA expert Dr Dennis Poddubnyy talks at #ACR20 press conference - Development and Validation of an #artificial_intelligence Approach for the Detection of Radiographic Sacroiliitis using MRI @RheumNow

Who will be more likely to have chronic reactive arthritis @RheumNow #ACR20 @CRASCRRheum

ACHILLES study: Only 56% of pts w/ clinical enthesitis had MRI+ heel enthesitis. MRI screening: HLAB27+ pts likely to be in MRI+ grp. @RheumNow #ACR20 Abstr#0447 #ACRbest https://t.co/m2cjDzYfyg

Dr.Gonzalez-Mazon describes surrogate markers assoc'd w #atherosclerosis in #axSpA: BASFI, BASMI, IBD, ESR, CRP, prednisone and DMARDs use. @RheumNow #ACR20 abst#0448 https://t.co/g27qA4qpPL

Extended 5 year study of secukinumab in AS patients showed sustained improvement of back pain, nocturnal back pain, AM stiffness, fatigue and LDA Abs#0364 @RheumNow #ACR20